Sökning: WFRF:(Battiwalla Minoo)
> (2020)
> Hashmi Shahrukh >
Age no bar :
Age no bar : A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma
-
- Munshi, Pashna N. (författare)
- MedStar Georgetown Univ Hosp, Washington, DC USA.
-
- Vesole, David (författare)
- Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA.
-
- Jurczyszyn, Artur (författare)
- Jagiellonian Univ Med Coll, Dept Hematol, Krakow, Poland.;Krakow Branch Polish Soc Haematol & Blood Transfu, Krakow, Poland.
-
visa fler...
-
- Zaucha, Jan Maciej (författare)
- Med Univ Gdansk, Dept Hematol & Transplantol, Gdansk, Poland.
-
- St Martin, Andrew (författare)
- Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
-
- Davila, Omar (författare)
- Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
-
- Agrawal, Vaibhav (författare)
- Indiana Univ Sch Med, Div Hematol Oncol, Indianapolis, IN 46202 USA.
-
- Badawy, Sherif M. (författare)
- Ann & Robert H Lurie Childrens Hosp Chicago, Div Hematol Oncol & Stem Cell Transplant, Chicago, IL USA.;Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA.
-
- Battiwalla, Minoo (författare)
- Sarah Cannon Blood Canc Network, Nashville, TN USA.
-
- Chhabra, Saurabh (författare)
- Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI 53226 USA.
-
- Copelan, Edward (författare)
- Atrium Hlth, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA.
-
- Kharfan-Dabaja, Mohamed A. (författare)
- Mayo Clin, Div Hematol Oncol, Blood & Marrow Transplantat Program, Jacksonville, FL USA.
-
- Farhadfar, Nosha (författare)
- Univ Florida, Div Hematol Oncol, Coll Med, Gainesville, FL USA.
-
- Ganguly, Siddhartha (författare)
- Univ Kansas Hlth Syst, Div Hematol Malignancy & Cellular Therapeut, Kansas City, KS USA.
-
- Hashmi, Shahrukh (författare)
- Mayo Clin, Dept Internal Med, Rochester, MN USA.;King Faisal Specialist Hosp & Res Ctr, Ctr Oncol, Riyadh, Saudi Arabia.
-
- Krem, Maxwell M. (författare)
- Univ Kentucky, Markey Canc Ctr, Coll Med, Lexington, KY USA.
-
- Lazarus, Hillard M. (författare)
- Case Western Reserve Univ, Univ Hosp Cleveland Med Ctr, Cleveland, OH 44106 USA.
-
- Malek, Ehsan (författare)
- Univ Hosp Cleveland, Seidman Canc Ctr, Med Ctr, Cleveland, OH 44106 USA.
-
- Meehan, Kenneth (författare)
- DartmouthHitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH USA.
-
Murthy, Hemant S. (författare)
-
- Nishihori, Taiga (författare)
- H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA.
-
- Olin, Rebecca L. (författare)
- Univ Calif San Francisco, San Francisco, CA 94143 USA.
-
- Olsson, Richard F. (författare)
- Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Stockholm, Sweden.
-
- Schriber, Jeffrey (författare)
- Virginia G Piper Canc Ctr, Canc Transplant Inst, Scottsdale, AZ USA.;Arizona Oncol, Scottsdale, AZ USA.
-
- Seo, Sachiko (författare)
- Dokkyo Med Univ, Dept Hematol & Oncol, Mibu, Tochigi, Japan.
-
- Shah, Gunjan (författare)
- Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplantat Serv, New York, NY USA.
-
- Solh, Melhem (författare)
- Northside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA.
-
- Tay, Jason (författare)
- Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
-
- Kumar, Shaji (författare)
- Mayo Clin Rochester, Dept Hematol, Rochester, MN USA.
-
- Qazilbash, Muzaffar H. (författare)
- Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
-
- Shah, Nina (författare)
- Univ Calif San Francisco, San Francisco, CA 94143 USA.
-
- Hari, Parameswaran N. (författare)
- Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
-
- D'Souza, Anita (författare)
- Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
-
visa färre...
-
MedStar Georgetown Univ Hosp, Washington, DC USA Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA. (creator_code:org_t)
- 2020-09-23
- 2020
- Engelska.
-
Ingår i: Cancer. - : WILEY. - 0008-543X .- 1097-0142. ; 126:23, s. 5077-5087
- Relaterad länk:
-
https://www.ncbi.nlm...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background Upfront autologous hematopoietic stem cell transplantation (AHCT) remains an important therapy in the management of patients with multiple myeloma (MM), a disease of older adults. Methods The authors investigated the outcomes of AHCT in patients with MM who were aged >= 70 years. The Center for International Blood and Marrow Transplant Research (CIBMTR) database registered 15,999 patients with MM in the United States within 12 months of diagnosis during 2013 through 2017; a total of 2092 patients were aged >= 70 years. Nonrecurrence mortality (NRM), disease recurrence and/or progression (relapse; REL), progression-free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models with age at transplantation as the main effect. Because of the large sample size, aPvalue <.01 was considered to be statistically significant a priori. Results An increase in AHCT was noted in 2017 (28%) compared with 2013 (15%) among patients aged >= 70 years. Although approximately 82% of patients received melphalan (Mel) at a dose of 200 mg/m(2)overall, 58% of the patients aged >= 70 years received Mel at a dose of 140 mg/m(2). On multivariate analysis, patients aged >= 70 years demonstrated no difference with regard to NRM (hazard ratio [HR] 1.3; 99% confidence interval [99% CI], 1-1.7 [P = .06]), REL (HR, 1.03; 99% CI, 0.9-1.1 [P = 0.6]), PFS (HR, 1.06; 99% CI, 1-1.2 [P = 0.2]), and OS (HR, 1.2; 99% CI, 1-1.4 [P = .02]) compared with the reference group (those aged 60-69 years). In patients aged >= 70 years, Mel administered at a dose of 140 mg/m(2)was found to be associated with worse outcomes compared with Mel administered at a dose of 200 mg/m(2), including day 100 NRM (1% [95% CI, 1%-2%] vs 0% [95% CI, 0%-1%];P = .003]), 2-year PFS (64% [95% CI, 60%-67%] vs 69% [95% CI, 66%-73%];P = .003), and 2-year OS (85% [95% CI, 82%-87%] vs 89% [95% CI, 86%-91%];P = .01]), likely representing frailty. Conclusions The results of the current study demonstrated that AHCT remains an effective consolidation therapy among patients with MM across all age groups.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Nyckelord
- age
- geriatric oncology
- myeloma
- transplantation
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Cancer
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Munshi, Pashna N ...
-
Vesole, David
-
Jurczyszyn, Artu ...
-
Zaucha, Jan Maci ...
-
St Martin, Andre ...
-
Davila, Omar
-
visa fler...
-
Agrawal, Vaibhav
-
Badawy, Sherif M ...
-
Battiwalla, Mino ...
-
Chhabra, Saurabh
-
Copelan, Edward
-
Kharfan-Dabaja, ...
-
Farhadfar, Nosha
-
Ganguly, Siddhar ...
-
Hashmi, Shahrukh
-
Krem, Maxwell M.
-
Lazarus, Hillard ...
-
Malek, Ehsan
-
Meehan, Kenneth
-
Murthy, Hemant S ...
-
Nishihori, Taiga
-
Olin, Rebecca L.
-
Olsson, Richard ...
-
Schriber, Jeffre ...
-
Seo, Sachiko
-
Shah, Gunjan
-
Solh, Melhem
-
Tay, Jason
-
Kumar, Shaji
-
Qazilbash, Muzaf ...
-
Shah, Nina
-
Hari, Parameswar ...
-
D'Souza, Anita
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
Cancer
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet